Research programme: drug discovery - Novartis/Morphochem
Latest Information Update: 15 Jul 2010
At a glance
- Originator Morphochem AG
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
- 13 Jun 2005 The research agreement between Morphochem and Novartis has been successfully completed
- 05 Dec 2003 Preclinical trials in Undefined in Germany (unspecified route)